ADRENALIN (epinephrine in sodium chloride) by Pfizer is adrenergic alpha-agonists [moa]. First approved in 2023.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
ADRENALIN is an intravenous epinephrine solution in sodium chloride approved by the FDA in April 2023. It is an alpha-adrenergic agonist that works by stimulating adrenergic receptors to produce rapid sympathomimetic effects. This formulation is used in acute care and emergency settings where rapid hemodynamic support is required.
Early growth-stage product with recent approval and minimal market penetration, suggesting opportunities for brand-building and market development roles.
Adrenergic alpha-Agonists
alpha-Adrenergic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
Comparative Efficacy of Hypertonic Saline vs Adrenaline Nebulization in Acute Bronchiolitis
Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection
Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline
Comparative Evaluation of Handling Characteristics of Two Adrenaline Autoinjectors,EpiPen in Comparison With Jext
Worked on ADRENALIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moADRENALIN represents an early-stage growth opportunity within Pfizer's critical care portfolio with 13 years of patent protection remaining. Roles on this brand offer exposure to acute care commercialization, hospital relationships, and competitive positioning in a niche but essential therapeutic area.